Because of variability in PTH measurement, the 2009 Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggested that patients with CKD-Stage 5D should control their PTH levels between 2- and 9-fold of the upper limit of normal2. The gene discussed is PTH; the disease is chronic kidney disease.